REG - OptiBiotix Health - Result of AGM

OptiBiotix HealthAnnouncement

26/07/2023 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230726:nRSZ2904Ha&default-theme=true

RNS Number : 2904H  OptiBiotix Health PLC  26 July 2023

26 July 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

Result of AGM

Directorate Change

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skin care
announces that at the AGM held earlier today, all resolutions were duly
passed.

 

Further to the announcement of 28 June 2023, the Company confirms that
Non-executive Directors Stephen Hammond and Chris Brinsmead have not put
themselves for re-election as Directors and have therefore, with immediate
effect, ceased to be Directors of the Company.

 

Neil Davidson, Chairman of OptiBiotix Health plc commented: "I would like to
take this opportunity to offer our thanks to Chris Brinsmead and Stephen
Hammond for their respective contributions and wise counsel during their time
on the Board."

 

The full voting results will be available on the website in due course here:
https://www.optibiotix-ir.com/content/investors/
(https://www.optibiotix-ir.com/content/investors/)

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)               Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGRFMBTMTTTBLJ